Sitagliptin HEC Pharm 50 mg Filmtabletten Vācija - vācu - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sitagliptin hec pharm 50 mg filmtabletten

hec pharm gmbh (8135805) - sitagliptinphosphat-monohydrat - filmtablette - sitagliptinphosphat-monohydrat (34150) 64,26 milligramm

Sitagliptin HEC Pharm 25 mg Filmtabletten Vācija - vācu - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sitagliptin hec pharm 25 mg filmtabletten

hec pharm gmbh (8135805) - sitagliptinphosphat-monohydrat - filmtablette - sitagliptinphosphat-monohydrat (34150) 32,13 milligramm

Sitagliptin Amarox 100 mg Filmtabletten Vācija - vācu - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sitagliptin amarox 100 mg filmtabletten

amarox pharma gmbh (8110952) - sitagliptinhydrochlorid - filmtablette - sitagliptinhydrochlorid (43764) 108,952 milligramm

Sitagliptin Amarox 50 mg Filmtabletten Vācija - vācu - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sitagliptin amarox 50 mg filmtabletten

amarox pharma gmbh (8110952) - sitagliptinhydrochlorid - filmtablette - sitagliptinhydrochlorid (43764) 54,476 milligramm

Sitagliptin Amarox 25 mg Filmtabletten Vācija - vācu - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sitagliptin amarox 25 mg filmtabletten

amarox pharma gmbh (8110952) - sitagliptinhydrochlorid - filmtablette - sitagliptinhydrochlorid (43764) 27,238 milligramm

Sitagliptin / Metformin hydrochloride Accord Eiropas Savienība - vācu - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , dreifach-kombinationstherapie) als ergänzung zu diät und bewegung bei patienten, die unzureichend kontrolliert auf ihren maximalen tolerierten dosis von metformin und sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.